Literature DB >> 17160481

Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States.

Sassan Pazirandeh1, Urmila Khettry, Fredric D Gordon, Robert H Resnick, Jessica E Murray, Sunil G Sheth.   

Abstract

UNLABELLED: Aberrant expression of cyclooxygenase-2 in hepatocellular carcinoma was described in Asia. Using immunohistochemistry, we studied the expression of cyclooxygenase-2 in hepatocellular carcinoma, chronic hepatitis, and cirrhosis in a US institution. A staining score of 0-5 representing the sum of an intensity score and a distribution score was used. The mean scores were 2.2+/-1.60 for chronic hepatitis, 4.37+/-1.15 for cirrhosis, and 4.76+/-0.54 for hepatocellular carcinoma. We found a significant difference in mean staining scores between chronic hepatitis and cirrhosis (p < 0.0001), as well as between chronic hepatitis and hepatocellular carcinoma (p < 0.0001). Fibrosis correlated with cyclooxygenase-2 staining score (r=0.65). IN
CONCLUSION: (1) Cyclooxygenase-2 expression is higher in cirrhosis and hepatocellular carcinoma when compared to chronic hepatitis. (2) Cyclooxygenase-2 expression correlates with the stage of fibrosis. (3) These results imply that in chronic hepatitis and possibly in cirrhosis, hepatocarcinogenesis may be a cyclooxygenase-2 dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160481     DOI: 10.1007/s10620-006-9184-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  44 in total

Review 1.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

2.  Postresection prognosis of patients with hepatocellular carcinoma.

Authors:  A Sugioka; T Tsuzuki; T Kanai
Journal:  Surgery       Date:  1993-06       Impact factor: 3.982

3.  Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

Authors:  C L Lai; J Y Lau; P C Wu; H Ngan; H T Chung; S J Mitchell; T J Corbett; A W Chow; H J Lin
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

4.  Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.

Authors:  K S Chapple; E J Cartwright; G Hawcroft; A Tisbury; C Bonifer; N Scott; A C Windsor; P J Guillou; A F Markham; P L Coletta; M A Hull
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.

Authors:  H Miura; T Miyazaki; M Kuroda; T Oka; R Machinami; T Kodama; M Shibuya; M Makuuchi; Y Yazaki; S Ohnishi
Journal:  J Hepatol       Date:  1997-11       Impact factor: 25.083

6.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

7.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

Authors:  H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

Review 9.  Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation.

Authors:  E Mor; R Tur-Kaspa; P Sheiner; M Schwartz
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391

10.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

Authors:  R Yamaguchi; H Yano; A Iemura; S Ogasawara; M Haramaki; M Kojiro
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

View more
  5 in total

1.  Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis.

Authors:  Soung Won Jeong; Jae Young Jang; Sae Hwan Lee; Sang Gyun Kim; Young Koog Cheon; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Joon Seong Lee; So-Young Jin; Chan Sup Shim; Boo Sung Kim
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

2.  Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachloride.

Authors:  Shi-Hang Tang; Jin-Hang Gao; Shi-Lei Wen; Huan Tong; Zhao-Ping Yan; Rui Liu; Cheng-Wei Tang
Journal:  Mol Med Rep       Date:  2017-02-02       Impact factor: 2.952

3.  Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Authors:  Soon Ha Kwon; Soung Won Jeong; Jae Young Jang; Ji Eun Lee; Sae Hwan Lee; Sang Gyune Kim; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; So-Young Jin
Journal:  Clin Mol Hepatol       Date:  2012-09-25

4.  Cyclooxygenase-2 Inhibitor Reduces Hepatic Stiffness in Pediatric Chronic Liver Disease Patients Following Kasai Portoenterostomy.

Authors:  Hye Kyung Chang; Eun Young Chang; Seonae Ryu; Seok Joo Han
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

5.  A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment.

Authors:  Yuko Takami; Susumu Eguchi; Masaki Tateishi; Tomoki Ryu; Kazuhiro Mikagi; Yoshiyuki Wada; Hideki Saitsu
Journal:  Hepatol Int       Date:  2016-02-04       Impact factor: 6.047

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.